EC 0225

Drug Profile

EC 0225

Alternative Names: DAVLBH and mitomycin-C conjugate; Desacetylvinblastine hydrazide and mitomycin-C conjugate; EC0225

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Endocyte
  • Class Antineoplastics; Drug conjugates; Vinca alkaloids
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Microtubule protein inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease) in USA (IV, Injection)
  • 01 Nov 2010 Endocyte completes a phase I trial in metastatic Cancer in USA
  • 04 Jun 2010 Interim adverse events and efficacy data from a phase I trial in Solid tumours presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top